Clinical Research Directory
Browse clinical research sites, groups, and studies.
Chidamide in HR-AML
Sponsor: Guangdong Second Provincial General Hospital
Summary
Acute myeloid leukemia (AML) patients with fusion gene-positive including core binding factor (CBF), mixed-lineage leukemia (MLL) gene rearrangement have a high incidence of relapse if they have continuously positive measurable residual disease (MRD) or ELN 2022-high risk chromosome abnormality and could not be bridged to allogenetic heamatopoitic stem cell transplantation (allo-HSCT). Histone deacetylase (HDAC) is known to abnormally recruit in these fusion gene-positive AML, and has been proven to be a promising therapy target. Whether HDAC inhibitor chidamide could be used as a maintenance therapy in these AML patients remains unknown. This study aims to evaluate the efficacy and safety of chidamide in the maintenance therapy of high-risk acute myeloid leukemia (AML) patients with core binding factor (CBF) and measurable residual disease (MRD) positivity, or ELN 2022-high risk fusion gene positive.
Official title: Efficacy and Safety of Chidamide in the Maintenance Therapy of High-Risk Acute Myeloid Leukemia Patients: A Multi-center Real-World Study
Key Details
Gender
All
Age Range
18 Years - 80 Years
Study Type
OBSERVATIONAL
Enrollment
33
Start Date
2026-07-27
Completion Date
2027-07-31
Last Updated
2026-09-16
Healthy Volunteers
No
Locations (1)
Department of Hematology, Guangdong Second Provincial General Hospital
Guangzhou, Guangdong, China